|
September 2008 · Vol. 57, No. 9 Suppl: S2
|
Introduction: The role of incretin therapy for type 2 diabetes in family medicine
Go to supplement
FACULTY
Michael E. Cobble, MD
Adjunct Faculty
University of Utah
School of Medicine
Salt Lake City, Canyons Medical Center
Sandy, Utah Jeffrey S. Freeman, DO, FACOI
Professor of Internal Medicine
Chairman, Division of Endocrinology and Metabolism
Philadelphia College of Osteopathic Medicine Philadelphia, Pennsylvania Alan J. Garber, MD, PhD
Professor
Departments of Medicine, Biochemistry and
Molecular Biology, and Molecular and Cellular Biology
Division of Endocrinology, Diabetes and Metabolism
Baylor College of Medicine
Houston, Texas Jens J. Holst, MD, PhD
Professor
Department of Biomedical Sciences
The Panum Institute, University of Copenhagen
Copenhagen, Denmark James R. LaSalle, DO
Private Practice
Excelsior Springs, Missouri Stephen J. Spann, MD, MBA
Chairman and Professor
Division of Family and Community
Baylor College of Medicine
Houston, Texas Jeff Unger, MD, FAAFP
Assistant Professor of Family Medicine
Loma Linda University School of Medicine
Loma Linda, California
Founder
The Unger Primary Care Medical Center
Associate Director of Metabolic Studies
Catalina Research Institute
Chino, California |
|
|
Faculty Disclosures
Dr Cobble is on the advisory boards for Abbott Laboratories, Eli Lilly and Company, and TheraSim, Inc.; and is on the speakers bureaus for Abbott Laboratories, AstraZeneca, Eli Lilly and Company, Forest Pharmaceuticals, and GlaxoSmithKline. Dr Freeman is on the advisory board for GlaxoSmithKline; is on the speakers bureaus for Daiichi Sankyo, Inc, GlaxoSmithKline, Merck & Co., Inc., and Novo Nordisk Inc.; and has ownership interest in Novo Nordisk Inc. Dr Garber is on the advisory board and speakers bureau for Novo Nordisk Inc. Dr Holst receives salary from Merck & Co., Inc. and Novo Nordisk Inc.; is on the advisory boards for Merck & Co., Inc., Novo Nordisk, Inc., and Roche; is on the speakers bureaus for Merck & Co., Inc. and Novo Nordisk, Inc.; and is engaged in contracted research with Merck & Co., Inc. and Novartis Pharmaceuticals Corporation. Dr LaSalle is on the advisory boards for AstraZeneca, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, and Novo Nordisk, Inc.; and is on the speakers bureaus for AstraZeneca, Glaxo SmithKline, and Novo Nordisk Inc. Dr Spann has no real or apparent conflicts of interest to disclose. Dr Unger is on the advisory board for Novo Nordisk Inc. and is on the speakers bureaus for Eli Lilly and Company, Novo Nordisk Inc., and sanofi-aventis. |
Learning Objectives
• List why physicians have not aggressively applied knowledge of the benefits of tight glycemic control into improved performance in clinical practice
• Interpret the physiological and clinical data supporting the role of the small intestine (incretins) in control of glucose homeostasis
• Explain the pharmacologic basis for why current therapies are limited by their inability to control both fasting and postprandial hyperglycemia
• Develop practice patterns that will encourage intensified treatment with the most appropriate medications, allowing patients to reach glycemic goals with minimal risk of hypoglycemia and weight gain
• Describe patient case scenarios in which incretin-based therapies may help meet the unmet needs of patients with diabetes
Sponsor Disclosure Statement
The content collaborators at the Primary Care Education Consortium report that there are no existing financial relationships to disclose.
Statement of Support
This program is sponsored by the Primary Care Education Consortium and is supported by an educational grant from Novo Nordisk Inc. Go to supplement |
